Background parenchymal enhancement on breast MRI: A comprehensive review. Issue 1 (19th April 2019)

• Record Type: Journal Article
• Authors: Liao, Geraldine J.; Henze Bancroft, Leah C.; Strigel, Roberta M.; Chitalia, Rhea D.; Kontos, Despina; Moy, Linda; Partridge, Savannah C.; Rahbar, Habib
• Is Part Of: Journal of magnetic resonance imaging. Volume 51:Issue 1(2020)
• Page Start: 43
• Page End: 61
• Publication Date: 2019-04-19
• Subjects: breast MRI -- breast cancer risk -- background parenchymal enhancement -- fibroglandular tissue -- biomarkers -- precision medicine; Magnetic resonance imaging -- Periodicals; 616
• DOI: 10.1002/jmri.26762
• Languages: English
• ISSNs: 1053-1807

Abstract

Abstract : The degree of normal fibroglandular tissue that enhances on breast MRI, known as background parenchymal enhancement (BPE), was initially described as an incidental finding that could affect interpretation performance. While BPE is now established to be a physiologic phenomenon that is affected by both endogenous and exogenous hormone levels, evidence supporting the notion that BPE frequently masks breast cancers is limited. However, compelling data have emerged to suggest BPE is an independent marker of breast cancer risk and breast cancer treatment outcomes. Specifically, multiple studies have shown that elevated BPE levels, measured qualitatively or quantitatively, are associated with a greater risk of developing breast cancer. Evidence also suggests that BPE could be a predictor of neoadjuvant breast cancer treatment response and overall breast cancer treatment outcomes. These discoveries come at a time when breast cancer screening and treatment have moved toward an increased emphasis on targeted and individualized approaches, of which the identification of imaging features that can predict cancer diagnosis and treatment response is an increasingly recognized component. Historically, researchers have primarily studied quantitative tumor imaging features in pursuit of clinically useful biomarkers. However, the need to segment less well‐defined areas of normal tissue for quantitative BPE measurements presents its own unique challenges. Furthermore, there is no consensus on the optimal timing on dynamic contrast‐enhanced MRI for BPE quantitation. This article comprehensively reviews BPE with a particular focus on its potential to increase precision approaches to breast cancer risk assessment, diagnosis, and treatment. It also describes areas of needed future research, such as the applicability of BPE to women at average risk, the biological underpinnings of BPE, and the standardization of BPE characterization. Level of Evidence: 3 Technical Efficacy Stage: 5 J. Magn. Reson. Imaging 2020;51:43–61.